Synopsis
0
KDMF
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] JDMF
Aspen API. More than just an API.
Registration Number : 303MF10070
Registrant's Address : Kloosterstraat 6, 5349 AB Oss, the Netherlands
Initial Date of Registration : 2021-04-22
Latest Date of Registration : 2021-04-22
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL-21 - 0.15MG;0.03MG **Fed...DOSAGE - TABLET;ORAL-21 - 0.15MG;0.03MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 20301
DOSAGE - TABLET;ORAL-28 - 0.1MG,0.125MG,0.15M...DOSAGE - TABLET;ORAL-28 - 0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG
USFDA APPLICATION NUMBER - 21090
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Desogestrel manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Desogestrel, including repackagers and relabelers. The FDA regulates Desogestrel manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Desogestrel API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Desogestrel manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Desogestrel supplier is an individual or a company that provides Desogestrel active pharmaceutical ingredient (API) or Desogestrel finished formulations upon request. The Desogestrel suppliers may include Desogestrel API manufacturers, exporters, distributors and traders.
click here to find a list of Desogestrel suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Desogestrel DMF (Drug Master File) is a document detailing the whole manufacturing process of Desogestrel active pharmaceutical ingredient (API) in detail. Different forms of Desogestrel DMFs exist exist since differing nations have different regulations, such as Desogestrel USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Desogestrel DMF submitted to regulatory agencies in the US is known as a USDMF. Desogestrel USDMF includes data on Desogestrel's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Desogestrel USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Desogestrel suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Desogestrel Drug Master File in Japan (Desogestrel JDMF) empowers Desogestrel API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Desogestrel JDMF during the approval evaluation for pharmaceutical products. At the time of Desogestrel JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Desogestrel suppliers with JDMF on PharmaCompass.
A Desogestrel CEP of the European Pharmacopoeia monograph is often referred to as a Desogestrel Certificate of Suitability (COS). The purpose of a Desogestrel CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Desogestrel EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Desogestrel to their clients by showing that a Desogestrel CEP has been issued for it. The manufacturer submits a Desogestrel CEP (COS) as part of the market authorization procedure, and it takes on the role of a Desogestrel CEP holder for the record. Additionally, the data presented in the Desogestrel CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Desogestrel DMF.
A Desogestrel CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Desogestrel CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Desogestrel suppliers with CEP (COS) on PharmaCompass.
A Desogestrel written confirmation (Desogestrel WC) is an official document issued by a regulatory agency to a Desogestrel manufacturer, verifying that the manufacturing facility of a Desogestrel active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Desogestrel APIs or Desogestrel finished pharmaceutical products to another nation, regulatory agencies frequently require a Desogestrel WC (written confirmation) as part of the regulatory process.
click here to find a list of Desogestrel suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Desogestrel as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Desogestrel API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Desogestrel as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Desogestrel and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Desogestrel NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Desogestrel suppliers with NDC on PharmaCompass.
Desogestrel Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Desogestrel GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Desogestrel GMP manufacturer or Desogestrel GMP API supplier for your needs.
A Desogestrel CoA (Certificate of Analysis) is a formal document that attests to Desogestrel's compliance with Desogestrel specifications and serves as a tool for batch-level quality control.
Desogestrel CoA mostly includes findings from lab analyses of a specific batch. For each Desogestrel CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Desogestrel may be tested according to a variety of international standards, such as European Pharmacopoeia (Desogestrel EP), Desogestrel JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Desogestrel USP).
LOOKING FOR A SUPPLIER?
